During the past decade, Northern Arizona Hematology & Oncology Associates conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 5 clinical trials were completed, i.e. on average, 250% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Northern Arizona Hematology & Oncology Associates" #1 sponsor was "Bristol-Myers Squibb" with 3 trials, followed by "NSABP Foundation Inc" with 2 trials sponsored, "Astellas Pharma Inc" with 1 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored and "Novartis Pharmaceuticals" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Northern Arizona Hematology & Oncology Associates" #1 collaborator was "US Oncology Research" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Cancer International Research Group (CIRG)" with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator and "OSI Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Northern Arizona Hematology & Oncology Associates" are "Metastatic Breast Cancer" (3 trials), "Breast Cancer" (2 trials), "Non-Small Cell Lung Cancer" (2 trials), "Advanced Breast Cancer" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Northern Arizona Hematology & Oncology Associates" in a lesser frequency.

Most popular intervention types in "Northern Arizona Hematology & Oncology Associates" are "Drug" (11 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (3 trials), "Bevacizumab" (2 trials), "Carboplatin" (2 trials), "Dasatinib" (2 trials) and "doxorubicin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Northern Arizona Hematology & Oncology Associates" are 6 trials for "Female" genders and 4 trials for "All" genders.

Currently, there are NaN active trials in "Northern Arizona Hematology & Oncology Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Northern Arizona Hematology & Oncology Associates, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Northern Arizona Hematology & Oncology Associates, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".